JMJ PHARMA · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of JMJ PHARMA is 2.1% (moderate). The 2024 annual accounts show equity of €110k and a net result of €14k. Equity is growing by ~3.2% per year across the filed fiscal years. Its solvency ranks better than 41% of 866 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 4 annual accounts.

Signals

2 signals · with evidence

Consistently profitable

Positive net result in the two most recent financial years (2023 and 2024).

View the result trend

Growing equity

Equity grew over 2022-2024. Profits are largely retained rather than distributed.

View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Deadline passed, not yet counted as missing

The deadline for the year that closed on 31-12-2025 passed on 31-07-2026, 13 days ago. Our copy of the deposit register trails the National Bank (measured: median 14 days, p99 45 days), so we only call this filing missing from 45 days past the deadline.

Latest accounts filed on time

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 29-07-2025, 2 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.

How we compute the deadline

The year end is derived from 4 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2024, that is 31-07-2025.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	29-07-2025	2 d early	2025-00334178
31-12-2023	31-07-2024	11-06-2024	50 d early	2024-00138008
31-12-2022	31-07-2023	02-06-2023	59 d early	2023-00116791
31-12-2021	31-07-2022	29-06-2022	32 d early	2022-20156744

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2021, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

2.1% Moderate

0%0,5%1,5%4%10%≥25%

Young company +Higher-failure-rate sector +Higher-failure-rate region +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

Turnover€1,000k+40.6%

EBIT margin-2.3%-7.4pp

Net result€14k+58.2%

Working capital€63k+3.2%

CSV export

Annual accounts & ratios

Source: NBB · 2024

Annual accounts filed on 29-07-2025 with the NBB · fiscal year 2024 · volledig

RevenueOperating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~3.2%/year over 4 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2024 · NACE 47, Retail trade · compared within the same schema type (full schema)

Metric	This company	Sector median	Position in the sector
Solvency	12.2%	17.3%	better than 41% of 866 sector peers
Net result	€14k	€14k	better than 50% of 867 sector peers
Equity	€110k	€100k	better than 52% of 868 sector peers
Gross operating margin	€175k	€213k	better than 45% of 794 sector peers
Staff costs	€82k	€219k	higher than 24% of 715 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P41

Stable position over 2021-2024 · n=578-866

Net result P50

Stable position over 2021-2024 · n=578-867

Equity P52

Stable position over 2021-2024 · n=580-868

Gross operating margin P45

Stable position over 2021-2024 · n=490-794

Describes the position versus peers, not a forecast.

Revenue

€1,000k

+40.6% 21-24

EBITDA

€90k

+2.5% 21-24

Net profit

€14k

+58.2% 21-24

Cash flow

€77k

+2.6% 21-24

Total assets

€901k

-5.3% 21-24

Equity

€110k

+14.7% 21-24

Working capital

€63k

+3.2% 21-24

Employees (FTE)

2

-29.2% 21-24

Staff costs

€82k

-31.7% 21-24

Income taxes

€2k

+478.1% 21-24

Debt

€792k

-7.5% 21-24

Debt ≤ 1y

€170k

+6.6% 21-24

Debt > 1y

€622k

-10.8% 21-24

Current ratio

1.37

-0.9% 21-24

Quick ratio

0.42

+16.0% 21-24

Solvency

12.2%

+21.1% 21-24

Debt / equity

7.22

-19.4% 21-24

ROE

12.8%

+37.9% 21-24

ROA

1.6%

+67.0% 21-24

Net margin

-3.5%

- 21-24

EBITDA margin

4.3%

-61.1% 21-24

Interest coverage

7.90

+14.2% 21-24

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2024
Deposit	volledig
Revenue	-
EBITDA	€90k
Net profit	€14k
Cash flow	€77k
Staff costs	€82k
Income taxes	€2k
Dividends	-
Total assets	€901k
Equity	€110k
Debt	€792k
of which ≤ 1y	€170k
of which > 1y	€622k
Working capital	€63k
Employees (FTE)	1.7

Ratios (computed)

	2024
Current ratio	1.37
Quick ratio	0.42
Working capital ratio	7.0%
Solvency	12.2%
Debt / equity	7.22
Long-term debt ratio	5.67
Interest coverage	7.90
Gross margin	-
Net margin	-
ROA	1.6%
ROE	12.8%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2024

Assets

Fixed assets €668k · 74.2% Current assets €233k · 25.8%

Equity & liabilities

Equity €110k · 12.2% Debt €792k · 87.8%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€901k
Fixed assets	21/28	€668k
Intangible fixed assets	21	€304k
Tangible fixed assets	22/27	€364k
Financial fixed assets	28	€349
Current assets	29/58	€233k
Stocks & contracts in progress	3	€162k
Amounts receivable within one year	40/41	€62k
Cash & bank	54/58	€9k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€901k
Equity	10/15	€110k
Contributions / capital	10/11	€100k
Accumulated profits (losses)	14	€10k
Amounts payable	17/49	€792k
Amounts payable after one year	17	€622k
Amounts payable within one year	42/48	€170k
Trade debts payable within one year	44	€77k
Income statement
Gross operating margin	9900	€175k
Operating result	9901	€27k
Financial income	75	€64
Financial charges	65	€11k
Result before taxes	9903	€16k
Income taxes	67/77	€2k
Net result for the period	9904	€14k
Result to be appropriated	9905	€14k

You're seeing the latest fiscal year only. Unlock 3 prior years (figures + ratios) with a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2024 · computed

66 / 100 Healthy

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

from the Crossroads Bank

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Jules Hagnoul(O) 11350 Orp-Jauche

Establishment units

1 location

Pharmacie Fraiture-Joos

Rue Jules Hagnoul(O) 1, 1350 Orp-JaucheApotheek

since 20212.316.032.673

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels1

Ground area59 m²

Buildings1

Building footprint55 m²

Volume (LiDAR)489 m³

Tallest building10.7 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Wallonia 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
25082B0409/00P000	Wallonia	59 m²	1 · 55 m²	10.7 m · 3 fl.

Methodology

via registered seat: 1

1 of 1 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Snowflake analysis

financial profile on 5 axes

61 / 100

Strong profile, led by stability.

All 5 axes are computed from data Checked has read.

Health 66

Profitability 64

Solvency 27

Growth 55

Stability 94

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers

Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon

The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works